Recombinant human tumor necrosis factor receptor - antibody fusion protein therapy of 26 cases of rheumatoid arthritis aged effect.docVIP

 PAGE \* MERGEFORMAT 7 Recombinant human tumor necrosis factor receptor - antibody fusion protein therapy of 26 cases of rheumatoid arthritis aged effect [Keywords:] recombinant human tumor necrosis factor receptor - antibody fusion protein; rheumatoid arthritis Injection of recombinant human tumor necrosis factor receptor - antibody fusion protein (trade name: etanercept (Etanercept, ETA)) is a human type tumor necrosis factor (TNF) receptor p75 in the extracellular segment and the Construction of IgG in the Fc fusion protein could specifically block the TNF-@ interaction with cell surface receptors (1). This controlled study was the treatment of active ETA elderly rheumatoid arthritis (RA) efficacy, to explore the best treatment elderly RA . 1 Materials and Methods 1.1 Clinical data of all cases from September 2006 to February 2008 Division of Rheumatology inpatient hospital, are in line with American Rheumatism Association 1987 revised diagnostic criteria for RA (2.) Treatment of them elderly group ETA, 20 cases 11 females, male 9, 60 ~ 79 years, mean (65 + -6 years). non-ETA group, 26 elderly patients, female in 16 cases, 10 males, aged 61 ~ 76 years (mean 65 + - 4) years old. ETA treatment of non-elderly group of 32 cases, female 24 cases, 8 males, aged 18 to 58 years, mean (46 + -11 years). 1.2 Methods senile group ETA ETA treatment of non-elderly group, 2 times per week application of ETA 25 mg subcutaneous injection, continuous treatment for 3 months, while oral methotrexate 10 mg / w or leflunomide 20 mg / d; non- oral methotrexate treatment of elderly group ETA 10 mg / w or leflunomide 20 mg / d. records of all patients before treatment and 3 months after treatment of rest pain, morning stiffness, swollen joint count and joint swelling index, joint tenderness, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), rheumatoid factor (RF) classification and anti-cyclic citrullinated peptide (CCP) antibodies and the DAS28 and the